stoxline Quote Chart Rank Option Currency Glossary
Immutep Limited (IMMP)
2.69  -0.02 (-0.74%)    06-17 16:00
Open: 2.69
High: 2.77
Volume: 193,475
Pre. Close: 2.71
Low: 2.6
Market Cap: 340(M)
Technical analysis
2024-06-17 5:24:14 PM
Short term     
Mid term     
Targets 6-month :  3.5 1-year :  3.9
Resists First :  3 Second :  3.33
Pivot price 2.77
Supports First :  2.45 Second :  2.03
MAs MA(5) :  2.68 MA(20) :  2.84
MA(100) :  2.56 MA(250) :  2.25
MACD MACD :  -0.1 Signal :  -0.1
%K %D K(14,3) :  39.7 D(3) :  32.8
RSI RSI(14): 46.4
52-week High :  3.33 Low :  1.58
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ IMMP ] has closed above bottom band by 33.8%. Bollinger Bands are 4.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 2.77 - 2.79 2.79 - 2.8
Low: 2.56 - 2.58 2.58 - 2.6
Close: 2.66 - 2.69 2.69 - 2.72
Company Description

Immutep Limited, a biotechnology company, engages in the research and development of pharmaceutical product candidates. The company develops immunotherapeutic products for the treatment of cancer and autoimmune diseases. Its lead product candidate is eftilagimod alpha (efti or IMP321), a recombinant protein that is in Phase IIb clinical trial as a chemoimmunotherapy combination for metastatic breast cancer. The company also develops TACTI-002, which is in a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer; TACTI-003 that is in Phase IIb clinical trial to treat HNSCC; and INSIGHT-004 and INSIGHT-003, which is in a Phase I clinical trial for the treatment of solid tumors, as well as INSIGHT-005 that is in Phase I/IIa clinical trial to treat solid tumors. Its other products include IMP761, an agonist of lymphocyte activation gene 3 for autoimmune disease; IMP701, an antagonist antibody that acts to stimulate T cell proliferation in cancer patients; and IMP731, a depleting antibody that removes T cells involved in autoimmunity. Immutep Limited has collaboration agreements with GlaxoSmithKline, Novartis, CYTLIMIC Inc., Merck & Co., Inc., Institute of Clinical Cancer Research, Merck KGaA, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. Immutep Limited was incorporated in 1987 and is based in Sydney, Australia.

Headline News

Sat, 15 Jun 2024
Immutep (NASDAQ:IMMP) Stock Price Crosses Above 50 Day Moving Average of $2.74 - Defense World

Sat, 15 Jun 2024
Immutep (NASDAQ:IMMP) Share Price Passes Above Fifty Day Moving Average of $2.74 - MarketBeat

Thu, 06 Jun 2024
Immutep Secures Strong Funding for Cancer Program - - TipRanks

Wed, 05 Jun 2024
Immutep slips after stock offering - MSN

Wed, 05 Jun 2024
Immutep stock slips after share offering (NASDAQ:IMMP) - Seeking Alpha

Wed, 05 Jun 2024
Immutep successfully completes institutional placement and institutional component of entitlement offer - GlobeNewswire

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 0 (M)
Shares Float 120 (M)
Held by Insiders 1.06e+009 (%)
Held by Institutions 0 (%)
Shares Short 1,460 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS -4.127e+007
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 0 %
Operating Margin -1 %
Return on Assets (ttm) 95.7 %
Return on Equity (ttm) -25.8 %
Qtrly Rev. Growth 3.93e+006 %
Gross Profit (p.s.) 14
Sales Per Share -23.41
EBITDA (p.s.) 0
Qtrly Earnings Growth -0.3 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow -42 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales -0.12
Price to Cash Flow 48.41
Stock Dividends
Dividend 0
Forward Dividend 3.73e+006
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android